Kura Oncology insider files Form 144 for 36,615-share sale on NASDAQ

Rhea-AI Filing Summary

Kura Oncology (KURA) Form 144 notice reports a proposed sale of 36,615 shares of common stock, to be executed on 09/29/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The shares were acquired as PSUs from the issuer on 09/27/2025 and carry an aggregate market value of $331,365.75 based on the filing. The filing states there were no securities sold by the reporting person in the prior three months.

The notice includes the standard representation that the seller does not possess any undisclosed material adverse information about the issuer and references Rule 10b5-1 plan disclosure as applicable. No other financial results, holdings, or related-party details are provided in the document.

Insights

Securities Analyst

TL;DR: Routine insider sale of PSUs, small relative to outstanding shares, procedural filing under Rule 144.

The Form 144 documents a planned market sale of 36,615 common shares acquired as performance stock units two days earlier. The trade is being routed through Morgan Stanley Smith Barney LLC and values the position at $331,365.75. Given total shares outstanding of 87,015,518 reported in the filing, the sale represents a very small fraction of the companys equity. The filing contains the usual attestations about material nonpublic information and notes no prior sales in the last three months, indicating this is a discrete, permitted disposition rather than part of a larger recent selling pattern.

Corporate Governance Expert

TL;DR: Compliance-focused disclosure; indicates adherence to Rule 144 procedures and standard insider representations.

The notice shows the reporting individual is complying with Rule 144 reporting requirements for an off-market sale of shares received as PSUs. The inclusion of acquisition and payment dates, broker details, and the sellers signature attestation align with regulatory expectations. Absence of prior three-month sales simplifies aggregation rules. The filing does not provide any governance issues or indications of broader insider selling.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	36615	331365.75	87015518	09/29/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/27/2025	PSU	Issuer			36615	09/29/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does KURA Form 144 report?

The filing reports a proposed sale of 36,615 common shares on 09/29/2025 via Morgan Stanley on NASDAQ, valued at $331,365.75.

How were the shares acquired according to the Form 144?

The shares were acquired as PSUs from the issuer on 09/27/2025.

Does the filing indicate other sales in the past three months?

No. The filing states Nothing to Report for securities sold during the past three months.

Who is the broker handling the sale?

The sale is to be executed through Morgan Stanley Smith Barney LLC, Executive Financial Services at 1 New York Plaza, 8th Floor, New York, NY.

What attestation does the seller make in the filing?

The reporting person represents they do not know any material adverse information about the issuer that has not been publicly disclosed and references Rule 10b5-1 plan disclosure if applicable.